A number of research analysts recently issued reports on the stock. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Morgan Stanley restated an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, Leerink Partners restated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th.